Altered RIG-I/DDX58-mediated innate immunity in dermatomyositis

Journal of Pathology

Volumn 233, Issue 3, 2014, Pages 258-268

  Suárez Calvet, Xavier ^a,b   Gallardo, Eduard ^a,b   Nogales Gadea, Gisela ^a,b   Querol, Luis ^a,b   Navas, Miquel ^a,b   Díaz Manera, Jordi ^a,b   Rojas Garcia, Ricard ^a,b   Illa, Isabel ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

DDX58; dermatomyositis; inflammatory myopathy; innate immunity; RIG I

Indexed keywords

BETA INTERFERON; INFLAMMASOME; INTERLEUKIN 1; MUSCLE PROTEIN; PROTEIN DDX60; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MIDDLE AGED; MOLECULAR RECOGNITION; MUSCLE CELL; MYOSITIS; MYOTUBE; POLYMYOSITIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION;

DDX58; DERMATOMYOSITIS; INFLAMMATORY MYOPATHY; INNATE IMMUNITY; RIG-I;

ADULT; AGED; CASE-CONTROL STUDIES; CELLS, CULTURED; DEAD-BOX RNA HELICASES; DERMATOMYOSITIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDIES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, INNATE; IMMUNOHISTOCHEMISTRY; INCLUSION BODIES; INTERFERON-BETA; MALE; MICRODISSECTION; MIDDLE AGED; MUSCLE FIBERS, SKELETAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMYOSITIS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3;

EID: 84902367750     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4346     Document Type: Article

References (40)

1. Engel AG, Franzini-Armstrong C,. Myology: Basic and Clinical. McGraw-Hill Medical: New York, 2004: 1321-1486.
2. Dalakas MC, Hohlfeld R,. Polymyositis and dermatomyositis. Lancet 2003; 362: 971-982.
3. Mammen AL,. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol 2011; 7: 343-354.
4. Larman HB, Salajegheh M, Nazareno R, et al., Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013; 73: 408-418.
5. Gallardo E, de Andres I, Illa I,. Cathepsins are upregulated by IFN-γ/STAT1 in human muscle culture: a possible active factor in dermatomyositis. J Neuropathol Exp Neurol 2001; 60: 847-855.
6. Nagaraju K, Casciola-Rosen L, Lundberg I, et al., Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005; 52: 1824-1835.
7. Nagaraju K, Raben N, Loeffler L, et al., Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA 2000; 97: 9209-9214.
8. Greenberg SA, Pinkus JL, Pinkus GS, et al., Interferon-α/β- mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57: 664-678.
9. Cappelletti C, Baggi F, Zolezzi F, et al., Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. Neurology 2011; 76: 2079-2088.
10. Salajegheh M, Kong SW, Pinkus JL, et al., Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010; 67: 53-63.
11. Greenberg SA, Sanoudou D, Haslett JN, et al., Molecular profiles of inflammatory myopathies. Neurology 2002; 59: 1170-1182.
12. Higgs BW, Liu Z, White B, et al., Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011; 70: 2029-2036.
13. D'Cunha J, Knight E, Jr., Haas AL, et al., Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci USA 1996; 93: 211-215.
14. Kawai T, Akira S,. Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci 2008; 1143: 1-20.
15. Ramos HJ, Gale M Jr., RIG-I like receptors and their signaling crosstalk in the regulation of antiviral immunity. Curr Opin Virol 2011; 1: 167-176.
16. Kim GT, Cho ML, Park YE, et al., Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. Clin Rheumatol 2010; 29: 273-279.
17. Tournadre A, Lenief V, Eljaafari A, et al., Immature muscle precursors are a source of interferon-β in myositis: role of Toll-like receptor 3 activation and contribution to HLA class I up-regulation. Arthritis Rheum 2012; 64: 533-541.
18. Poeck H, Bscheider M, Gross O, et al., Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1β production. Nat Immunol 2010; 11: 63-69.
19. Salminen A, Kauppinen A, Kaarniranta K,. Emerging role of NF-κB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell Signal 2012; 24: 835-845.
20. Malathi K, Dong B, Gale M, Jr,., et al. Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature 2007; 448: 816-819.
21. Dalakas MC,. Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev 2012; 11: 203-206.
22. Illa I, Gallardo E, Gimeno R, et al., Signal transducer and activator of transcription 1 in human muscle: implications in inflammatory myopathies. Am J Pathol 1997; 151: 81-88.
23. De Luna N, Gallardo E, Sonnet C, et al., Role of thrombospondin 1 in macrophage inflammation in dysferlin myopathy. J Neuropathol Exp Neurol 2010; 69: 643-653.
24. Hornung V, Ellegast J, Kim S, et al., 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006; 314: 994-997.
25. Kuznik A, Bencina M, Svajger U, et al., Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011; 186: 4794-4804.
26. de Luna N, Gallardo E, Soriano M, et al., Absence of dysferlin alters myogenin expression and delays human muscle differentiation 'in vitro'. J Biol Chem 2006; 281: 17092-17098.
27. Smyth GK,. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: article 3.
28. Loo YM GMJ,. Immune signaling by RIG-I-like receptors. Immunity 2011; 34: 680-692.
29. Uaesoontrachoon K, Cha HJ, Ampong B, et al., The effects of MyD88 deficiency on disease phenotype in dysferlin-deficient A/J mice: role of endogenous TLR ligands. J Pathol 2013; 231: 199-209.
30. Cufi P, Dragin N, Weiss JM, et al., Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis. Ann Neurol 2013; 73: 281-293.
31. Miyashita M, Oshiumi H, Matsumoto M, et al., DDX60, a DEXD/H box helicase, is a novel antiviral factor promoting RIG-I-like receptor-mediated signaling. Mol Cell Biol 2011; 31: 3802-3819.
32. Kato H, Sato S, Yoneyama M, et al., Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005; 23: 19-28.
33. Seo JY, Yaneva R, Cresswell P,. Viperin: a multifunctional, interferon-inducible protein that regulates virus replication. Cell Host Microbe 2011; 10: 534-539.
34. Castanier C, Garcin D, Vazquez A, et al., Mitochondrial dynamics regulate the RIG-I-like receptor antiviral pathway. EMBO Rep 2010; 11: 133-138.
35. Yasukawa K, Oshiumi H, Takeda M, et al., Mitofusin 2 inhibits mitochondrial antiviral signaling. Sci Signal 2009; 2: ra47.
36. Hinson ER, Cresswell P,. The antiviral protein, viperin, localizes to lipid droplets via its N-terminal amphipathic α-helix. Proc Natl Acad Sci USA 2009; 106: 20452-20457.
37. Li CK, Knopp P, Moncrieffe H, et al., Overexpression of MHC class I heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis. Am J Pathol 2009; 175: 1030-1040.
38. Chakrabarti A, Jha BK, Silverman RH,. New insights into the role of RNase L in innate immunity. J Interferon Cytokine Res 2011; 31: 49-57.
39. Casciola-Rosen L, Nagaraju K, Plotz P, et al., Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201: 591-601.
40. Nakashima R, Imura Y, Kobayashi S, et al., The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 2010; 49: 433-440.